Creative Biolabs has extensive experience in coronavirus research. Provide comprehensive high-quality coronavirus (SARS-CoV-2, SARS-CoV, MERS-CoV, etc.) related services and products. This slide provides a brief introduction to SARS-CoV-2. If you need more knowledge, products and services related to SARS-CoV-2, please follow us.

1. SARS-CoV-2 Introduction

2. End of 2019 - Wuhan, China
Now – Spread in over 200 countries (WHO)
January 30, 2020 - PHEIC February 11, 2020 - Named SARS-CoV-2
January, 2020 - Named 2019-nCoV
SARS-CoV-2 Outbreak Process

3. Mammals Birds and
Mammals
The SARS-CoV-2 virus that causes COVID-19 belongs to the
Coronaviridae family.
SARS-CoV-2
Coronaviruses Family

4. Spike Glycoprotein (S)
Get the virus into the cell
Hemagglutinin-esterase (HE)
May facilitate the virus to initially adsorb
the cell membrane
RNA and N Protein
N protein is related to the formation of
nucleocapsid in RNA genome
E-Protein
The smallest and most mysterious
Envelope
SARS-CoV-2 Structure
M-Protein
Virus germination and envelope formation

5. ACE2
1 Fusion
2 Replicate Assembly3
Release4
SARS-CoV-2 Life Cycle

6. Screen the existing broad-spectrum
antiviral drugs.
Use existing molecular libraries and
databases to screen for molecules that may
have a therapeutic effect on SARS-CoV-2.
Develop specific drugs based on the
genomic information and pathological
characteristics of SARS-CoV-2.
1 2 3
SARS-CoV-2 Treatment Strategies

7. 3-1. Target to the Host
• Enhance immune response - such as the
release of interferon.
• Block the signal pathways
required for virus replication.
• Target viral and cell surface receptor
proteins (ACE2).
Object of Specific Drugs

8. • Prevent viral RNA synthesis - target
to the genetic material of the virus.
• Inhibit virus replication - target to
key enzymes of the virus.
• Block the virus’s binding to human
cell receptors or inhibiting the
virus’self-assembly process - target
to the structural proteins of the virus.
Object of Specific Drugs
3-2. Target to SARS-CoV-2

9. Monoclonal antibody/convalescent plasma for ACE2:
Prevent the virus into the host cell.1
science.sciencemag.org/content/367/6485/1412
Camostat mesylate: Prevent SARS-CoV-2 into the cell
by acting on TMPRSS2.2
Lopinavir-Ritonavir: Inhibition of protease activity of
SARS-CoV-2.3
Ribavirin- May inhibit mRNA capping.4
RNA Synthesis Inhibitors: Inhibits SARS-CoV-2 RNA
synthesis and replication.
5
Neuraminidase Inhibitors (NAIs)-Interfere with the
release of progeny influenza virus from infected
host cells.
66
SARS-CoV-2 Treatment Strategies
NAIs
RNA Synthesis
Inhibitors
①
②
③
④
⑤
⑥

10. SARS-CoV-2 Preclinical Research
Drug Discovery Services
In Vitro Diagnostic (IVD) Development
• Anti-SARS-CoV-2 Drug Discovery
• Antibody & Immunoassay Development Services
Creative Biolabs’ SARS-CoV-2 Services
• SARS-CoV-2 Vaccine Discovery
• SARS-CoV-2 Preclinical Research
• Molecular Diagnostic Assay Development Services
• SARS-CoV-2 Related Detection Kits

11. Antibody
Recombinant Proteins
Plasmids
PCR Primers & Probes
Detection Kits
SARS-CoV-2
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
MERS-CoV
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
SARS-CoV
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
Other Coronavirus
RNA Extraction Kits
RNA Extraction Kit
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
Key Receptor ACE2
Creative Biolabs’ SARS-CoV-2 Products

12. Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-biolabs.com
Web: www.creative-biolabs.com
Contact Us